Enteric coated preparation for preventing and treating hyperuricemia and gout

Abstract

Provided is an enteric preparation for preventing and curing hyperuricemia and gout. The employing essential component of the preparation is enteric capsules of uricase. The causes of the hyperuricemia and the gout are that uric acid is over generated and / or the uric acid is diminished in discharging, and metabolic diseases increasing the density of serum uric acid. About one third of the uric acid of the human body is defecated from intestinal canals, and the uric acid entering the canals still can be reabsorbed. When the hyperuricemia and the gout happen, the proportion of the uric acid defecated from the intestinal canals is increased. The uricase is capable of rapidly effectively dissociating the uric acid. The uricase of the enteric preparation after being orally taken is disintegrated in the intestinal canals and is diffused from blood into the uric acid of the intestinal canals, preventing the uric acid from reabsorbing, thereby reducing the density of the serum uric acid, achieving the purposes of preventing and curing the hyperuricemia and the gout. The oral uricase has the characteristics of non-absorbent property by the intestinal canals, keeping out of blood circulation, no producing of antibodies of organisms and allergic response, providing a new method for preventing and curing the hyperuricemia and the gout.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to an enteric-coated preparation for preventing and treating hyperuricemia and gout. Background technique [0002] Incidence of hyperuricemia and gout: In recent years, the incidence of gout and hyperuricemia has been on the rise. In some areas of my country, the incidence of hyperuricemia has reached 13.3%, and the age of onset is becoming younger. Huge burden, and closely related to hypertension, hyperlipidemia, atherosclerosis, obesity, and insulin resistance, has become an early marker for identifying metabolic syndrome (Zhang Ruifen, Zhao Jing. Research progress in the pathogenesis of gout. Practical Drugs and Clinics, 2007; 10(4): 244-246), and it is also a common disease in the world today, especially among middle-aged and elderly men. Therefore, hyperuricemia and gout are increasingly threatening human health. [0003] The pathogenesis of hyperuricemia and gout: Gout is a...

AI Technical Summary

Problems solved by technology

However, in the Phase I clinical trial using recombinant PEG-modified uricase (PEG-uricase), it was found that 4-24 mg PEG-uricase was subcutaneously injected in 13 patients with hyperuricemia (11 of which were gout). The uricase can indeed significantly reduce the blood uric acid level, but unfortunately, 5 of the patients developed antibodies against PEG-modified uricase, and PEG-modified uricase could not be detected in the body 10 days after the drug

Images